Contact

Address

04, Clinical School Accomm, St Vincents Hospital

Phone

03 9288 2591

Email

kv@unimelb.edu.au

Credentials

Position
Professor Infectious Diseases
Medicine - St Vincent's Hospital
Education
Doctor of Philosophy
University of New South Wales
Bachelor of Medicine & Bachelor of Surgery
University of New South Wales
ORCID

0000-0002-1176-5442

Prof. Kumar Visvanathan

Professor Infectious Diseases
Medicine - St Vincent's Hospital
232 Scholarly works
16 Projects

HIGHLIGHTS

  • 2021

    Journal article

    P302 Serum IL-6 is associated with treatment refractoriness in acute severe ulcerative colitis
    DOI: 10.1093/ecco-jcc/jjab076.426
  • 2021

    Journal article

    A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia
    DOI: 10.1111/jvh.13495
  • 2021

    Journal article

    Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B.
    DOI: 10.1002/hep.31795
  • 2020

    Conference Proceedings

    HBV-STOP study: Large hepatitis B virus flares off nucleot(s)ide analog therapy cause large innate immune response
  • 2018

    Research Grant

    NOVEL EARLY DETECTION STRATEGY FOR LIVER CANCER USING HEPATITIS B SPLICE VARIANTS TO EXPEDIATE DIAGNOSIS AND IMPROVE TREATMENT OUTCOME
  • 2014

    Research Grant

    A STUDY OF TREATMENT DISCONTINUATION FOR CHRONIC HEPATITIS B PATIENTS
  • 2013

    Research Grant

    IL28B GENOTYPE AND HCV INFECTION IN THE LIVER
Kumar Visvanathan

Latest Honours,
Awards and Fellowships

2006
Frank Fenner Award for Advanced Research in Infectious Diseases Australian Society of Infectious Disease
2004
President's Award American Association for the Study of Liver Disease
1993
Postgraduate Scholarship NHMRC
1991
Travelling Scholarship Royal Australian College of Physicians

RECENT SCHOLARLY WORKS

  • 2020

    Conference Proceedings

    Validation of a novel point-of-care alanine aminotransferase test in patients with viral hepatitis
  • 2020

    Conference Proceedings

    Quantitative hepatitis B surface antigen levels: A new biomarker for chronic hepatitis B infection
  • 2020

    Conference Proceedings

    A prospective study of nucleot(s)ide analog discontinuation in non-cirrhotic patients with HBeAg-negative chronic hepatitis B: Interim analysis identifies different viral kinetics after stopping tenofovir versus entecavir
  • 2020

    Journal article

    Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age
    DOI: 10.1016/j.jhep.2020.06.031
  • 2020

    Journal article

    The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy
    DOI: 10.3390/v12090934
  • 2020

    Journal article

    A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare
    DOI: 10.1016/s0168-8278(20)30674-7

RECENT PROJECTS

  • 2020

    Research Grant

    Investigating the medium and long-term impact of COVID-19 on patients
  • 2018

    Research Grant

    NOVEL EARLY DETECTION STRATEGY FOR LIVER CANCER USING HEPATITIS B SPLICE VARIANTS TO EXPEDIATE DIAGNOSIS AND IMPROVE TREATMENT OUTCOME